With a $10 billion market cap, it’s hard to call Alnylam (ALNY)
overlooked, but I do believe the shares of this maturing biotech are
undervalued as the company approaches a window that should see multiple
new product approvals through 2020. Most recently, Alnylam has offered
up some data that suggest growing opportunities outside its core
amyloidosis programs.
Read more here:
Alnylam Pharmaceuticals Continues To Develop Options Outside Of Amyloidosis
No comments:
Post a Comment